Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Sep;58(3):368–372. doi: 10.1038/bjc.1988.221

Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission.

G Pizzolo 1, L Trentin 1, F Vinante 1, C Agostini 1, R Zambello 1, M Masciarelli 1, C Feruglio 1, F Dazzi 1, G Todeschini 1, M Chilosi 1, et al.
PMCID: PMC2246608  PMID: 3179190

Abstract

A long term follow-up study has been undertaken in 33 patients with acute non-lymphoblastic leukaemia (ANLL) in order to establish whether a correlation exists between the clinical course and the immunologic pattern of lymphoid subpopulations. Peripheral blood lymphoid cells have been investigated longitudinally (each 1 to 4 months) during complete remission (CR), by morphologic, phenotypic and functional analyses. Particular attention has been paid to the evaluation of the natural killer (NK) cell compartment, by the detection of cells expressing an NK-related phenotype and by NK in vitro assay. Among the patients so far evaluable, 20 relapsed (R) and 10 are long survivors in CR 'off therapy' (LS). The most relevant finding was represented by statistically higher values of NK activity observed in LS vs. R patients (P less than 0.01). The removal of adherent cells before the NK assay, performed to investigate the possible inhibitory effect on NK function played by the macrophage component, abolished this difference, due to a selective increase of NK function in the R group. The longitudinal study revealed that NK activity tended to decrease in individual patients who subsequently relapsed. These data suggest a possible role of NK cells in the relapse control of ANLL, although it cannot be excluded that the low level of NK activity observed in the R group is the result of impending relapse rather than its cause.

Full text

PDF
368

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum F. R., Dahlberg S., Thomas E. D., Buckner C. D., Cheever M. A., Clift R. A., Crowley J., Deeg H. J., Fefer A., Greenberg P. D. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med. 1984 Nov;101(5):581–588. doi: 10.7326/0003-4819-101-5-581. [DOI] [PubMed] [Google Scholar]
  2. Bacigalupo A., Van Lint M. T., Frassoni F., Marniont A. Graft-versus-leukemia effect following allogeneic bone marrow transplantation. Br J Haematol. 1985 Dec;61(4):749–751. doi: 10.1111/j.1365-2141.1985.tb02890.x. [DOI] [PubMed] [Google Scholar]
  3. Barton J. C., Conrad M. E. Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med. 1979 Feb;90(2):188–190. doi: 10.7326/0003-4819-90-2-188. [DOI] [PubMed] [Google Scholar]
  4. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  5. Beran M., Hansson M., Kiessling R. Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood. 1983 Mar;61(3):596–599. [PubMed] [Google Scholar]
  6. Brunda M. J., Herberman R. B., Holden H. T. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol. 1980 Jun;124(6):2682–2687. [PubMed] [Google Scholar]
  7. Champlin R. E., Ho W. G., Gale R. P., Winston D., Selch M., Mitsuyasu R., Lenarsky C., Elashoff R., Zighelboim J., Feig S. A. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985 Mar;102(3):285–291. doi: 10.7326/0003-4819-102-3-285. [DOI] [PubMed] [Google Scholar]
  8. Cheever M. A., Greenberg P. D., Fefer A. Therapy of leukemia by nonimmune syngeneic spleen cells. J Immunol. 1980 May;124(5):2137–2142. [PubMed] [Google Scholar]
  9. Chemello L., Mondelli M., Bortolotti F., Schiavon E., Pontisso P., Alberti A., Rondanelli E. G., Realdi G. Natural killer activity in patients with acute viral hepatitis. Clin Exp Immunol. 1986 Apr;64(1):59–64. [PMC free article] [PubMed] [Google Scholar]
  10. Combe B., Pope R., Darnell B., Kincaid W., Talal N. Regulation of natural killer cell activity by macrophages in the rheumatoid joint and peripheral blood. J Immunol. 1984 Aug;133(2):709–713. [PubMed] [Google Scholar]
  11. Dienstag J. L., Bhan A. K. Enhanced in vitro cell-mediated cytotoxicity in chronic hepatitis B virus infection: absence of specificity for virus-expressed antigen on target cell membranes. J Immunol. 1980 Nov;125(5):2269–2276. [PubMed] [Google Scholar]
  12. Dinsmore R., Kirkpatrick D., Flomenberg N., Gulati S., Kapoor N., Brochstein J., Shank B., Reid A., Groshen S., O'Reilly R. J. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood. 1984 Mar;63(3):649–656. [PubMed] [Google Scholar]
  13. Fearon E. R., Burke P. J., Schiffer C. A., Zehnbauer B. A., Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med. 1986 Jul 3;315(1):15–24. doi: 10.1056/NEJM198607033150103. [DOI] [PubMed] [Google Scholar]
  14. Fontana L., De Rossi G., De Sanctis G., Bottari V., Avvisati G., Perricone R., Mandelli F. PHA-ICC, ADCC and NK in patients with ANLL in CR: human fibroblastic interferon fails to increase NK-active cell frequency. Leuk Res. 1984;8(5):885–891. doi: 10.1016/0145-2126(84)90109-7. [DOI] [PubMed] [Google Scholar]
  15. Gale R. P., Champlin R. E. Bone marrow transplantation in acute leukaemia. Clin Haematol. 1986 Aug;15(3):851–872. [PubMed] [Google Scholar]
  16. Gale R. P., Foon K. A. Acute myeloid leukaemia: recent advances in therapy. Clin Haematol. 1986 Aug;15(3):781–810. [PubMed] [Google Scholar]
  17. Hall T. J., Chen S. H., Brostoff J., Lydyard P. M. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol. 1983 Nov;54(2):493–500. [PMC free article] [PubMed] [Google Scholar]
  18. Kärre K., Klein G. O., Kiessling R., Klein G., Roder J. C. Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature. 1980 Apr 17;284(5757):624–626. doi: 10.1038/284624a0. [DOI] [PubMed] [Google Scholar]
  19. Lanier L. L., Le A. M., Phillips J. H., Warner N. L., Babcock G. F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983 Oct;131(4):1789–1796. [PubMed] [Google Scholar]
  20. Lopez C., Kirkpatrick D., Sorell M., O'Reilly R. J., Ching C. Association between pre-transplant natural kill and graft-versus-host disease after stem-cell transplantation. Lancet. 1979 Nov 24;2(8152):1103–1107. doi: 10.1016/s0140-6736(79)92506-6. [DOI] [PubMed] [Google Scholar]
  21. Lotzová E. Effector immune mechanisms in cancer. Nat Immun Cell Growth Regul. 1985;4(6):293–304. [PubMed] [Google Scholar]
  22. McGeorge M. B., Russell E. C., Mohanakumar T. Immunologic evaluation of long-term effects of childhood ALL chemotherapy: analysis of in vitro NK- and K-cell activities of peripheral blood lymphocytes. Am J Hematol. 1982 Feb;12(1):19–27. doi: 10.1002/ajh.2830120104. [DOI] [PubMed] [Google Scholar]
  23. Rees J. K., Gray R. G., Swirsky D., Hayhoe F. G. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet. 1986 Nov 29;2(8518):1236–1241. doi: 10.1016/s0140-6736(86)92674-7. [DOI] [PubMed] [Google Scholar]
  24. Reinherz E. L., Schlossman S. F. Current concepts in immunology: Regulation of the immune response--inducer and suppressor T-lymphocyte subsets in human beings. N Engl J Med. 1980 Aug 14;303(7):370–373. doi: 10.1056/NEJM198008143030704. [DOI] [PubMed] [Google Scholar]
  25. Rotoli B., Formisano S., Martinelli V., Nigro M. Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. N Engl J Med. 1982 Dec 30;307(27):1712–1713. doi: 10.1056/NEJM198212303072721. [DOI] [PubMed] [Google Scholar]
  26. Semenzato G., Pizzolo G., Agostini C., Ambrosetti A., Zambello R., Trentin L., Luca M., Masciarelli M., Chilosi M., Vinante F. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. Blood. 1986 Jul;68(1):293–296. [PubMed] [Google Scholar]
  27. Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979 May 10;300(19):1068–1073. doi: 10.1056/NEJM197905103001902. [DOI] [PubMed] [Google Scholar]
  28. Whitecar J. P., Jr, Bodey G. P., Freireich E. J., McCredie K. B., Hart J. S. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep. 1972 Aug;56(4):543–550. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES